Abvc biopharma entered into a term sheet to license global rights of cns drugs with the indications of mdd and adhd to aibtl biopharma at the valuation of $667 million

Fremont, ca, oct. 26, 2023 (globe newswire) -- via newmediawire   –  abvc biopharma, inc.  (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that it entered into a legal binding term sheet regarding a multi-year, global licensing agreement with aibtl biopharma (aibtl) for the company's cns drugs with the indications of mdd (major depressive disorder) and adhd (attention deficit hyperactivity disorder) (the "licensed products"). the potential license will cover the licensed products' clinical trial, registration, manufacturing, supply, and distribution rights.
ABVC Ratings Summary
ABVC Quant Ranking